Collins Glenn M, Herbst Seth J, Aqua Keith A
Institute for Women's Health and Body, Wellington, Forida, USA.
Surg Technol Int. 2004;13:115-9.
Transcervical hysteroscopic permanent sterilization is currently Federal Drug Administration (FDA) approved. The hysteroscopic approach obviates the need for general anesthesia and surgical incision. The device is a dynamically expanding micro-insert that, when placed in the proximal portion of the fallopian tube, generates a benign tissue response that results in anchoring of the device and subsequent occlusion of the tube. The current trial of 745 women seeking birth control from Australia, Europe, and the United States were evaluated for successful micro-insert placement at three months. Comfort, safety, and return to normal activity were evaluated. All patients were followed for five years and returned for annual gynecologic status. Procedure time was 18 minutes, 92% returned to work in one day. There were no reported pregnancies among these patients in 27,526 months. The transcervical approach for sterilization represents ease of application, low morbidity, and convenience to the patient.
经宫颈宫腔镜永久性绝育术目前已获得美国食品药品监督管理局（FDA）批准。宫腔镜手术无需全身麻醉和手术切口。该装置是一种动态扩张的微型植入物，放置在输卵管近端时，会引发良性组织反应，从而使装置固定并随后阻塞输卵管。目前对来自澳大利亚、欧洲和美国的745名寻求避孕的女性进行了试验，评估三个月时微型植入物放置是否成功。对舒适度、安全性和恢复正常活动情况进行了评估。所有患者均随访五年，并每年返回进行妇科检查。手术时间为18分钟，92%的患者在一天内恢复工作。在27526个月的随访期内，这些患者均未报告怀孕。经宫颈绝育方法操作简便、发病率低且对患者方便。
